The medical treatment of Parkinson disease from James Parkinson to George Cotzias

Abstract

It took exactly 150 years since James Parkinson's description in 1817 of the illness bearing his name until the development of effective therapy for this disorder, namely, the introduction of high-dosage levodopa by George Cotzias in 1967. During the first 50 years, no effective therapy was available, but neurologists reported using different agents, including metals. Then, around 1867, Charcot found solanaceous alkaloids to be somewhat helpful, and these became the accepted and popular therapy for the next 75 years. When basic scientists discovered that these alkaloids had central antimuscarinic activity, pharmaceutical chemists developed synthetic chemical agents that were equally effective, with possibly less adverse effects, and around 1950 these synthetic drugs became the standard medical therapy for Parkinson's disease (PD). The link between dopamine and PD did not take place until 1957, 140 years after Parkinson's Essay. The clue came from research on reserpine, a drug derived from the Rauwolfia plant that caused a sedative effect, now recognized as a drug-induced parkinsonian state. Initial investigations revealed that reserpine caused the release and depletion of serotonin stores in the brain. With that knowledge, Arvid Carlsson, a young pharmacologist in Sweden, decided to explore the possibility that reserpine might also affect brain catecholamines. In his now famous, elegant, and simple experiment, he showed that injecting l-dopa, the precursor of catecholamines, alleviated the reserpine-induced parkinsonian state in animals, whereas the precursor of serotonin failed to do so. Carlsson then developed a highly sensitive assay to measure dopamine, and his lab found that dopamine is selectively present in high concentrations in the striatum and that administered l-dopa could restore the dopamine depleted by reserpine. Carlsson postulated that all these findings implicate dopamine in motor disorders. Oleh Hornykiewicz, a young pharmacologist in Vienna, on being aware of the regional localization of brain dopamine, decided to measure it in the brains of people who had PD and postencephalitic parkinsonism. In 1960, he reported finding markedly depleted dopamine in the striatum in these conditions. Immediately after, Hornykiewicz teamed up with the geriatrician, Walther Birkmayer, to inject small doses of l-dopa intravenously (IV) into PD patients. They found benefit and pursued this treatment, but the gastrointestinal side effects limited the dosage, and many neurologists were doubtful that the effects from l-dopa were any better than those with antimuscarinic agents. A number of neurologists tested such low doses of IV l-dopa and even higher oral dosages, but without showing any dramatic benefit, not better than the antimuscarinics. Some of these studies were small, controlled trials. This general lack of efficacy with l-dopa prevailed, and neurologists were discouraged about l-dopa until 1967, when George C. Cotzias, a neuropharmacologist in New York, reported his results. He thought that PD may be result...

Dopamine and the Brainstem Locomotor Networks: From Lamprey to Human

“…These locomotor deficits are traditionally associated with a loss of the ascending dopaminergic projections from the substantia nigra pars compacta (SNc) to the basal ganglia (Carlsson et al, 1958; Carlsson, 1959; Sano et al, 1959; Poirier and Sourkes, 1965; Sourkes and Poirier, 1965; Albin et al, 1989; Ehringer and Hornykiewicz, 1998; Kravitz et al, 2010; Roseberry et al, 2016, for review see Fahn, 2015). In turn, the basal ganglia project down to the Mesencephalic Locomotor Region (MLR), a brainstem region that controls locomotion in vertebrates (Shik et al, 1966; for review see Ryczko and Dubuc, 2013, Figure 1).…”

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

“…It is widely used [13] and, since its advent in 1967, has revolutionized the treatment of PD [14], improving the quality of life of millions of people worldwide [15]. However it is associated with motor complications such as wearing off, 'on-off' phenomena and dyskinesias after prolonged therapy for more than 5 years [16].…”

Neurochemical correlation between major depressive disorder and neurodegenerative diseases

“…These alterations lead to a progressive loss of dopaminergic neurons and the clinical signs of illness [63][64][65][66][67][68]. However, these pathologic changes are not limited to the substantia nigra pars compacta.…”